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Purpose. Patients may achieve a better quality of life (QOL) after IMRT compared with conventional 3D Radiotherapy (RDT) for
head and neck cancer patients. The period of study was from 2005 to 2009.
Material and method. A retrospective study onQOL in patients treated for head and neck cancer and thosewhohave been subjected
to the standard questionnaire about their physical status andquality of life QLQ-H&N35. A total of 168 patients have been treated,
79 were treated with 3D Radiation (2005–2008) and 89 patients with integrated boost IMRT (2008–2009). 66 patients were evaluated
by the standard questionnaire about their physical status QLQ-H & N35 (22 with 3D and 44 with IMRT) speciﬁcally xerostomia
and chronic sequelae in the oral cavity area.
Results. 3D 60% of patients received postoperative RDT. Radical RDT 40%± chemotherapy. Tumor stage at diagnosis is 60% ≥T3
and 65% ≥N1; In N+ more frequently N2b. Patients were treated as follows: 4 for nasopharynx, 6 oropharynx, 10 relapses of
larynx, hypopharynx or oral cavity after surgery, 1 multifocal, 9 hypopharynx, 12 oral cavity, 20 supraglottic, 16 glottic and 1
subglottis. 22 patients were evaluated for chronic xerostomia (GII ≥50%, and 30% GI). Mean score QOL was 49 (37–97). IMRT 36%
of patients were treated with radical surgery followed by RDT or RDT-QT. For patients who did not undergo surgery, the most
common treatment was concomitant RDT-QT. 52% of cases ≥T3 tumor stage, nodal stage 72% ≥N1. In N+, 31%N1 and 20% N2b.
In regards to primary tumor, the cases seen were; 16 nasopharynx, 20 oropharynx, 2 relapses of larynx and 4 of oral cavity, 3
multicenter, 11 hypopharynx, 6 oral cavity, 16 supraglottic and 11 glottic. 41 patients were evaluated for chronic xerostomia (GII
≥36%, and 32% GI Mean score QOL was 40 (34-67)).
Conclusion. Patients treated with IMRT show a better quality of life compared to those treated with conventional radiation therapy,
reducing the appearance of more severe sequelae.
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Introduction. For years the use of induction chemotherapy (ICT) followed by external radiotherapy (ERT) with concomitant cetux-
imab was the standard of treatment in patients with locally advanced squamos cell carcinoma of the head and neck (SCCHN).
In selected patients, induction chemotherapy could facilitate organ perservation, avoid morbility surgery and improve quality of
life of the patient.
Purpose. To investigate the tolerance of ICT with docetaxel, cisplatin, and 5-Fluorouracil (TPF) followed by ERT with concomitant
cetuximab in the treatment of patients with SCCHN.
Patients and methods. This trial enrolled 28 eligible patients with Stage III or IV nonmetastatic oropharyngeal and hypopharyngeal
carcinoma who received ICT followed by ERT with concomitant cetuximab were retrospectively analyzed. Clinical safety (weight,
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